European journal of pharmacologyHumansAngiogenesis InhibitorsChoroidal NeovascularizationMacular DegenerationRandomized Controlled Trials as Topic
Comparative efficacy and safety of faricimab, aflibercept, conbercept, and ranibizumab for neovascular age-related macular degeneration: A systematic review and network meta-analysis.
Shanduo Cen, Shixin Liu, Miaomiao Zhao, Lei Tang
Published: 202610.1016/j.ejphar.2025.178406
Abstract
BACKGROUND: Existing meta-analyses of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration focus mainly on ranibizumab and aflibercept, with limited data on newer agents (faricimab, conbercept). This netw…
Preview only. Read the full abstract at the source